OSAGF yields 4.05% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 9
Combined, OSAGF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSAGF + JNJ for your $10,000?
OSRAM Licht AG provides various lighting products and solutions worldwide. The company operates through three segments: Opto Semiconductors, Automotive, and Digital. It manufactures light-emitting diodes (LEDs) that are used in general lighting, automotive, consumer, and industrial applications; and infrared, laser, and optical sensors for the automotive, smartphone, wearable, general lighting, industrial lighting, and projection sectors, as well as lightings for plants. The company also develops and produces lamps and lighting systems for stages, cinemas, and studios; LED-based plant cultivation systems; lighting solutions for industrial and medical applications, such as high-intensity UV lamps and LED illumination for clothing; and automotive systems based on LED and laser technology, and other customer-specific system solutions. In addition, it develops, produces, and markets LED light engines and light management systems, as well as electronic ballasts, LED drivers, and LED modules. Further, the company is involved in the provision of products in the areas of architectural interior and exterior lighting, as well as professional interior lighting solutions. It provides its products under the OSRAM, Vixar, SYLVANIA, Traxon, e:cue, Digital Lumens, Fluence, Clay Paky, ADB Stagelight, OSRAM CONTINENTAL, LED Engin, and b,a,g, brands. The company was formerly known as Kyros A AG and changed its name to OSRAM Licht AG in November 2012. The company was founded in 1906 and is headquartered in Munich, Germany. OSRAM Licht AG operates as a subsidiary of ams AG.
Full OSAGF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.